NCT02960659View on ClinicalTrials.gov

Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 9, 2017

Primary Completion Date

May 20, 2022

Study Completion Date

May 20, 2022

Conditions
Type 2 Diabetes
Interventions
DRUG

Liraglutide

Liraglutide (6mg/ml, 3ml ) solution for subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6mg, 1.2mg or 1.8mg.

DRUG

Metformin

Metformin 500mg oral tablet

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

Sponsors
All Listed Sponsors
collaborator

Children's National Research Institute

OTHER

lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH